Eton Pharmaceuticals, Inc. ETON
Set alert
At close · Oct 30
After hours · Oct 30, 5:36 PM ET
- YTD
- +208.57%
- 1 year
- +185.92%
- Open
- 53.33
- Prev close
- 53.67
- Mkt cap
- 1.49B
- Vol
- 333.69K
- Avg vol
- 562.95K
- EPS
- 0.40
- P/E
- 130.45
- Div yield
- 0.00%
More statistics
- Low
- 51.89
- High
- 53.62
- Forward P/E
- 20.47
- Beta
- 0.90
- Short ratio
- 3.18
- Inst. own
- 71.64%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 56.16
- 200-d avg
- 35.52
- 1y target
- 71.50
News
3 days ago globenewswire.com
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…
6 days ago defenseworld.net
Eton Pharmaceuticals, Inc. $ETON Shares Newly Bought by Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the undefined quarter, according to its most recent disclosure with the Securities and…
2 weeks ago benzinga.com
Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
Eton Pharmaceuticals licenses Aquestive’s LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Maintains $70 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and maintains $70 price target.
-
2 weeks ago benzinga.com
Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually…
2 weeks ago globenewswire.com
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
DEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…
3 weeks ago defenseworld.net
Financial Survey: Eton Pharmaceuticals (NASDAQ:ETON) vs. Cronos Group (NASDAQ:CRON)
Cronos Group (NASDAQ: CRON - Get Free Report) and Eton Pharmaceuticals (NASDAQ: ETON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the…
3 weeks ago zacks.com
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.
1 month ago globenewswire.com
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…
1 month ago defenseworld.net
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Has Consensus Price Target of $67.50 According to Brokerages
Eton Pharmaceuticals, Inc. (NASDAQ: ETON - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat…
1 month ago benzinga.com
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
2 months ago defenseworld.net
Connor Clark & Lunn Investment Management Ltd. Makes New $476,000 Investment in Eton Pharmaceuticals, Inc. $ETON
Connor Clark and Lunn Investment Management Ltd. purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the undefined quarter, according to its most recent 13F filing with the…
2 months ago defenseworld.net
BlackRock Inc. Invests $68.63 Million in Eton Pharmaceuticals, Inc. $ETON
BlackRock Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The…
2 months ago defenseworld.net
Eton Pharmaceuticals, Inc. $ETON Stock Holdings Increased by Bank of America Corp DE
Bank of America Corp DE boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 37.8% in the undefined quarter, according to the company in its most recent disclosure with the…
2 months ago defenseworld.net
Bank of Nova Scotia Acquires New Position in Eton Pharmaceuticals, Inc. $ETON
Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
2 months ago benzinga.com
Jim Cramer: 'You Could Make Some Money With This 5.6% Yield'
Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on BillionToOne, and calls Eton Pharma a winner.
2 months ago globenewswire.com
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…
2 months ago benzinga.com
Dow Falls Over 100 Points, Records Weekly Loss: Investor Sentiment Weakens, but Fear Index Remains in ‘Greed’ Zone
The Fear & Greed Index, which measures market sentiment, declined while remaining in the Greed zone. U.S. stocks closed lower, with the Dow Jones falling over 100 points.
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $68
Canaccord Genuity analyst Gary Nachman maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $60 to $68.
2 months ago fool.com
Why Eton Pharmaceuticals Is Top of the Class Today
Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
2 months ago benzinga.com
Dow Falls Over 100 Points; US Consumer Sentiment Declines In August
Dow falls 0.26% while Nasdaq drops 0.51%. Energy shares rise 1.3%, tech stocks fall 0.6%. US retail sales down 0.6%, consumer sentiment declines.
-
2 months ago benzinga.com
B. Riley Securities Reiterates Buy on Eton Pharmaceuticals, Raises Price Target to $70
B. Riley Securities analyst Madison El-Saadi reiterates Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $40 to $70.
2 months ago seekingalpha.com
Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These
Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales…
2 months ago benzinga.com
Heartflow, Eton Pharmaceuticals, Nu Holdings And Other Big Stocks Moving Higher On Friday
U.S. stocks up, Dow Jones 0.1% higher. HeartFlow (HTFL) shares rise 26.5% on better-than-expected earnings. Other big gains include ETON, VALN, IMXI.
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report…
2 months ago benzinga.com
Applied Industrial Technologies To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday
Top analysts changed outlook on top names. Mizuho raised price target for AIT from $355 to $400. See how analysts view AIT, ETON, PLGO, BRZE, VERI, POWL, AMAT, and YETI.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $70
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $65 to $70.
2 months ago benzinga.com
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.
2 months ago seekingalpha.com
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Eton Pharmaceuticals Q2 Earnings Call Highlights
Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and…
2 months ago zacks.com
Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.1 per share a year ago.
2 months ago benzinga.com
Eton Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript
Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved…
-
2 months ago benzinga.com
Eton Pharmaceuticals Q2 Adj. EPS $0.43 Beats $0.10 Estimate, Sales $37.568M Beat $27.119M Estimate
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.10 by 290.91 percent. This is a 530 percent increase over losses of…
2 months ago globenewswire.com
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
DEER PARK, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $65
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $57 to $65.
2 months ago defenseworld.net
Bank of New York Mellon Corp Trims Stake in Eton Pharmaceuticals, Inc. $ETON
Bank of New York Mellon Corp cut its position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 12.9% in the first quarter, according to the company in its most recent 13F filing with the Securities…
-
2 months ago benzinga.com
Eton Pharmaceuticals Licenses U.S. Rights To Rare Disease Product Candidate ASN-001 From Auson Pharmaceuticals For Treatment Of Proliferating Superficial Infantile Hemangiomas
ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timololComplementary product to HEMANGEOL® (propranolol hydrochloride)…
2 months ago globenewswire.com
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
DEER PARK, Ill., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…
-
3 months ago benzinga.com
Eton Pharmaceuticals Submits FDA Prior Approval Supplement For Its New Formulation Of KHINDIVI Oral Solution
New formulation of KHINDIVI (hydrocortisone) oral solution successfully showed bioequivalence to ALKINDI SPRINKLE (hydrocortisone) oral granules, the FDA-approved hydrocortisone granule formulation,…
-
3 months ago benzinga.com
Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $62
Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $40 to $62.
-
3 months ago benzinga.com
Canaccord Genuity Initiates Coverage On Eton Pharmaceuticals with Buy Rating, Announces Price Target of $60
Canaccord Genuity analyst Gary Nachman initiates coverage on Eton Pharmaceuticals (NASDAQ:ETON) with a Buy rating and announces Price Target of $60.
-
5 months ago benzinga.com
Eton Pharma Enters Into Supply And Distribution Agreement For US Commercialization Rights To IMPAVIDO From Affiliate Of Knight Therapeutics
IMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially…
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $57
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $52 to $57.
-
5 months ago benzinga.com
Full Transcript: Eton Pharmaceuticals Q1 2026 Earnings Call
Full Transcript: Eton Pharmaceuticals Q1 2026 Earnings Call
-
5 months ago benzinga.com
Eton Pharmaceuticals Q1 Adj. EPS $0.14 Beats $0.09 Estimate, Sales $24.266M Beat $22.312M Estimate
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.09 by 55.56 percent. This is a 100 percent increase over earnings of…
-
6 months ago benzinga.com
Eton Pharma Announces First Patient Dosed In Pilot Clinical Study Assessing Efficacy Of ET-700 For Treatment Of Wilson Disease; Topline Study Results Expected In H2 2026
Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the…
7 months ago benzinga.com
The Insider Report: Markets Wade into Geopolitical Abyss
The Insider Report: Markets Wade into Geopolitical Abyss